Ulrike Schmidt Selected Research

Ulrike Schmidt Research Topics

Disease

48	Anorexia Nervosa 02/2024 - 06/2010
27	Feeding and Eating Disorders (Eating Disorder) 01/2022 - 04/2010
21	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 11/2021 - 05/2011
11	Mental Disorders (Mental Disorder) 05/2024 - 01/2013
8	Bulimia Nervosa 10/2023 - 10/2004
7	Binge-Eating Disorder (Binge Eating Disorder) 10/2023 - 08/2015
7	Schizophrenia (Dementia Praecox) 01/2021 - 01/2013
6	Wounds and Injuries (Trauma) 12/2019 - 05/2011
5	Neoplasms (Cancer) 02/2021 - 10/2003
4	Obesity 01/2024 - 11/2017
4	Bulimia (Binge Eating) 01/2022 - 04/2010
3	Overweight 01/2024 - 10/2019
3	Weight Gain 01/2021 - 01/2018
3	Body Weight (Weight, Body) 01/2018 - 11/2013
3	Hepatocellular Carcinoma (Hepatoma) 05/2007 - 09/2005
2	Neoplasm Metastasis (Metastasis) 02/2021 - 09/2014
2	Psychotic Disorders (Schizoaffective Disorder) 03/2020 - 01/2018
2	Starvation 01/2017 - 01/2010
2	Anxiety Disorders (Anxiety Disorder) 01/2015 - 01/2013
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2023
1	Opioid-Related Disorders (Opiate Addiction) 01/2023
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2023
1	Liver Diseases (Liver Disease) 01/2023
1	COVID-19 02/2022
1	Neuroinflammatory Diseases 09/2021
1	Carcinoma (Carcinomatosis) 02/2021
1	Colorectal Neoplasms (Colorectal Cancer) 02/2021
1	Lung Neoplasms (Lung Cancer) 02/2021
1	Body-Weight Trajectory 01/2021
1	Emaciation 01/2020
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2019
1	Panic Disorder (Panic Attack) 10/2018

Drug/Important Bio-Agent (IBA)

9	salicylhydroxamic acid (SHAM)IBA 01/2022 - 04/2010
7	Proteins (Proteins, Gene)FDA Link 11/2021 - 09/2005
7	Biomarkers (Surrogate Marker)IBA 10/2021 - 01/2013
6	CytokinesIBA 01/2022 - 09/2014
5	Antipsychotic Agents (Antipsychotics)IBA 02/2024 - 07/2013
4	Messenger RNA (mRNA)IBA 10/2021 - 10/2018
4	NeuropeptidesIBA 01/2021 - 05/2012
3	mesoglycanIBA 02/2023 - 01/2015
3	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2022 - 01/2021
3	Tacrolimus Binding Proteins (FKBP)IBA 11/2021 - 01/2015
3	InterleukinsIBA 10/2021 - 09/2014
3	LipidsIBA 01/2019 - 07/2013
3	Cytosine DeaminaseIBA 05/2007 - 09/2005
3	ProdrugsIBA 05/2007 - 09/2005
3	Flucytosine (Ancobon)FDA Link 05/2007 - 09/2005
2	Olanzapine (Zyprexa)FDA Link 02/2024 - 01/2017
2	Dexamethasone (Maxidex)FDA LinkGeneric 10/2021 - 01/2019
2	Antidepressive Agents (Antidepressants)IBA 01/2021 - 01/2013
2	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2019 - 11/2016
2	Dopamine (Intropin)FDA LinkGeneric 01/2016 - 01/2016
2	MicroRNAs (MicroRNA)IBA 06/2015 - 01/2013
2	Fluoxetine (Prozac)FDA LinkGeneric 01/2013 - 01/2012
2	DNA (Deoxyribonucleic Acid)IBA 05/2012 - 10/2003
2	EnzymesIBA 11/2005 - 09/2005
1	Alanine Transaminase (SGPT)IBA 01/2023
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2023
1	Cocaine (Cocaine HCl)IBA 01/2023
1	Heroin (Diamorphine)IBA 01/2023
1	IronIBA 01/2023
1	Lisdexamfetamine Dimesylate FDA Link 11/2022
1	tacrolimus binding protein 4 (FKBP52)IBA 11/2021
1	Type I Tumor Necrosis Factor ReceptorsIBA 10/2021
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 10/2021
1	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 10/2021
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 10/2021
1	Interleukin-12 (IL 12)IBA 08/2021
1	Interleukin-7 (Interleukin 7)IBA 08/2021
1	Small Interfering RNA (siRNA)IBA 02/2021
1	Matrix Metalloproteinases (MMPs)IBA 02/2021
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 02/2021
1	Cadherins (E-Cadherin)IBA 02/2021
1	Oxytocin Receptors (Oxytocin Receptor)IBA 01/2021
1	Oxytocin (Pitocin)FDA LinkGeneric 01/2021
1	ElectrolytesIBA 05/2020
1	PhytohemagglutininsIBA 11/2019
1	InterferonsIBA 11/2019
1	Pro-Opiomelanocortin (Proopiomelanocortin)IBA 01/2019
1	MelanocortinsIBA 01/2019
1	Melanocyte-Stimulating Hormones (MSH)IBA 01/2019
1	Blood Glucose (Blood Sugar)IBA 01/2019
1	ProstaglandinsIBA 01/2018
1	methyl nicotinateIBA 01/2018
1	ORALIT (ORS)IBA 01/2018

Therapy/Procedure

28	Therapeutics 05/2024 - 11/2005
15	Transcranial Magnetic Stimulation 01/2022 - 04/2010
11	Transcranial Direct Current Stimulation 02/2023 - 11/2013
4	Caloric Restriction 01/2024 - 01/2020
4	Deep Brain Stimulation 06/2021 - 11/2013
4	Ambulatory Care (Outpatient Care) 11/2020 - 07/2014
3	Medical Day Care (Partial Hospitalization) 01/2023 - 01/2011
3	Secondary Prevention 01/2019 - 07/2013
2	Drug Therapy (Chemotherapy) 01/2018 - 10/2004
2	Neurofeedback 11/2017 - 11/2013
1	Opiate Substitution Treatment 01/2023
1	Patient Discharge 07/2022
1	Patient Isolation 02/2022
1	Aftercare (After-Treatment) 07/2020
1	Cognitive Training 10/2019